Literature DB >> 22798108

Gastrointestinal stromal tumors: A multicenter study of 1160 Turkish cases.

Gülen Bülbül Doğusoy1.   

Abstract

BACKGROUND/AIMS: The aim of this multicenter study was to determine the histopathological features and immunohistochemical profiles of gastrointestinal stromal tumors diagnosed in Turkish patients.
MATERIAL AND METHODS: Twenty-eight participating centers registered their gastrointestinal stromal tumor cases on a nationwide database. The diagnosis of gastrointestinal stromal tumor relied upon hematoxylin & eosin features and the results of antibody panel including CD117, CD34, desmin, smooth muscle actin, S-100 protein, and Ki67. The database consisted of parameters including age, gender, location, and all other histopathological and immunohistochemical findings. Statistical analysis was performed using Pearson, Kruskal-Wallis, Mann-Whitney U, and Spearman tests.
RESULTS: From all of the gastrointestinal stromal tumors in the database, 1160 cases with a male to female ratio of 1.22 and a mean age of 56.75 years were included in the study. The most common location was the stomach (45.0%), followed by the small intestine, omentum-peritoneum, large intestine, and esophagus (32.0%, 12.6%, 9.3%, 1.1%, respectively). The risk groups were distributed as: 6.1% very low, 21.7% low, 19.3% intermediate, and 53% high-risk cases. Many histopathologic findings were correlated with risk groups. CD117 was positive in 95.3% of gastrointestinal stromal tumors, whereas CD34 was positive in 74.9%, smooth muscle actin in 45.9%, desmin in 9.2%, and S-100 in 19.1.%. Though no significant relation was found between CD117 expression and tumor location, CD34, smooth muscle actin and Ki67 expressions significantly varied in different locations (p=0.001) and risk groups.
CONCLUSIONS: The results of this multicenter study demonstrated that features other than tumor size and mitosis and immune markers other than CD117 and Ki67 included in the antibody panel seem to be useful as predictive risk factors.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22798108

Source DB:  PubMed          Journal:  Turk J Gastroenterol        ISSN: 1300-4948            Impact factor:   1.852


  16 in total

1.  Unexpectedly ease surgery for a worrisome abdominal mass: Pedunculated GISTs.

Authors:  Adil Baskiran; Emrah Otan; Cemalettin Aydin; Cuneyt Kayaalp
Journal:  Int J Surg Case Rep       Date:  2013-07-16

2.  Emergency Laparoscopic Gastrectomy for Intraperitoneal Ruptured Gastric Gastrointestinal Stromal Tumor.

Authors:  Kutay Saglam; Fatih Sumer; Cihan Gokler; Ayse Nur Akatli; Cuneyt Kayaalp
Journal:  J Gastrointest Cancer       Date:  2019-12

Review 3.  Primary gastrointestinal stromal tumors: Current advances in diagnostic biomarkers, prognostic factors and management of its duodenal location.

Authors:  Yuesi Zhong; Meihai Deng; Bo Liu; Cheng Chen; Mingliang Li; Ruiyun Xu
Journal:  Intractable Rare Dis Res       Date:  2013-02

4.  Expression of L1 protein correlates with cluster of differentiation 24 and integrin β1 expression in gastrointestinal stromal tumors.

Authors:  Yue DU; Haihong Zhang; Zhongmin Jiang; Guowei Huang; Wenli Lu; Hesheng Wang
Journal:  Oncol Lett       Date:  2015-04-02       Impact factor: 2.967

Review 5.  Giant gastrointestinal stromal tumour of rare sarcomatoid epithelioid subtype: case study and literature review.

Authors:  Gustaw Lech; Wojciech Korcz; Emilia Kowalczyk; Tomasz Guzel; Marcin Radoch; Ireneusz Wojciech Krasnodębski
Journal:  World J Gastroenterol       Date:  2015-03-21       Impact factor: 5.742

6.  Carney triad, SDH-deficient tumors, and Sdhb+/- mice share abnormal mitochondria.

Authors:  Eva Szarek; Evan R Ball; Alessio Imperiale; Maria Tsokos; Fabio R Faucz; Alessio Giubellino; François-Marie Moussallieh; Izzie-Jacques Namer; Mones S Abu-Asab; Karel Pacak; David Taïeb; J Aidan Carney; Constantine A Stratakis
Journal:  Endocr Relat Cancer       Date:  2015-03-25       Impact factor: 5.678

7.  Neoadjuvant imatinib: longer the better, need to modify risk stratification for adjuvant imatinib.

Authors:  Anant Ramaswamy; Deepak Jain; Arvind Sahu; Joydeep Ghosh; Priya Prasad; Kedar Deodhar; Nitin Shetty; Shripad Banavali; Shailesh Shrikhande; Vikas Ostwal
Journal:  J Gastrointest Oncol       Date:  2016-08

8.  Long-term survival after enucleation of a giant esophageal gastrointestinal stromal tumor.

Authors:  Zhi-Min Mu; Yuan-Cai Xie; Xu-Xing Peng; Hai Zhang; Gang Hui; Hao Wu; Ji-Xian Liu; Bao-Kun Chen; Da Wu; Yi-Wang Ye
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

9.  Clinicopathologic factors predicting outcomes in patients with gastrointestinal stromal tumors of the rectum and colon.

Authors:  Zhongguo Zhou; Zhanpeng Chen; Minshan Chen; Ruojing Wang; Ying Yin; Yuan Yao
Journal:  Tumour Biol       Date:  2013-12-28

10.  Oesophageal GIST-A rare breed case report and review of the literature.

Authors:  Kristof Nemeth; Christopher Williams; Majid Rashid; Mark Robinson; Ashraf Rasheed
Journal:  Int J Surg Case Rep       Date:  2015-02-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.